PolyNovo

PolyNovo's journey began with a vision to revolutionize wound care through advanced materials science. Born from the innovative labs of the CSIRO in 2004, the company was established to commercialize a unique biodegradable polymer technology known as NovoSorb. This patented platform was developed to address a critical gap in reconstructive surgery: the need for a synthetic, biocompatible material that could support tissue regeneration without the risks associated with biological grafts. What started as a scientific breakthrough in Melbourne, Australia, has since evolved into a global medical device company dedicated to redefining healing for patients with complex wounds.

Over the years, PolyNovo has transformed from a research-focused entity into a commercial powerhouse. The company's flagship product, NovoSorb BTM (Biodegradable Temporising Matrix), received FDA clearance in 2015, marking a pivotal moment in its history. This regulatory milestone paved the way for rapid expansion into the United States and other key international markets. Today, PolyNovo's solutions are used by surgeons worldwide to treat severe burns, trauma, and surgical wounds, significantly improving patient outcomes. With a growing global footprint and a robust pipeline of new applications, PolyNovo continues to push the boundaries of regenerative medicine, staying true to its mission of saving lives and restoring the quality of life for survivors of traumatic injuries.